Guest post by Doro Shin, Thought Leadership Manager at Informa Pharma Intelligence
Fortune Magazine once stated, “Alliances have become an integral part of contemporary strategic thinking,” and the pharma industry is no stranger to this concept. In fact, an upcoming whitepaper to be released at next month’s BIO-Europe® in Cologne, Germany, did find that the current state of drug development is indeed a collaborative endeavor, and the majority of companies, both public and private, possess partnered products within their pipelines. Within the remainder of the report, Partnering in the Pharma world: BIO-Europe® and Industry trends 2012–2015, Pharma Intelligence delves into the world of collaboration within the industry to gain insight into this oft-used strategy, overall and within the ever popular oncology space.
After reviewing the top opportunities for unpartnered pipeline products, the report then dissects meeting activity that occurred at BIO-Europe between 2012 and 2015, since meetings are a crucial aspect of the partnering process, particularly face-to-face. According to anonymized company and meeting data from EBD Group’s partneringONE® database, which was limited to companies who identified their main sector as Biotechnology – Therapeutics and Diagnostics (Biotech) or Pharma, meeting activity has and continues to grow. Both the number of meeting requests and the total number of companies requesting meetings increased each year at similar rates, which resulted in a steady average number of requests made per company. The largest jump in activity was observed in 2013 where the number of meetings and the number of requesting companies grew by 13% and 15%, respectively. Activity growth was much smaller in subsequent years, with year-on-year changes ranging between 1-3%.
As seen in Figure 1, the most meeting requests were made by Biotech companies to Pharma companies (B to P). This was the most common pairing each year, following by Pharma to Pharma (P to P). Although B to P had the highest levels each year, this was the only sector pairing to seemingly decrease their activity over time (excluding an uptick in 2013). Meeting activity for all other sector pairings consistently increased over time, causing the differences in meeting counts between the different pairings to slowly shrink.
To round out the report, we provided the landscape of all partnership deals since 2012. Since the BIO-Europe meeting data is anonymized, the analysis was unable to directly link BIO-Europe meetings with any subsequent deals, however, this landscape provides a view of the potential outcomes of these in-person meetings (or perhaps potential incentives to engage in meetings). For instance, there was a large growth in activity at the 2013 BIO-Europe, both in the number of meetings as well as the number of companies requesting meetings. Within the world of deals, both the total deal value and volume jump up in 2015. Just prior to the 2013 Bio-Europe, 2012 had both the lowest deal volume and value. Considering the growing interest in partnerships within pharma, perhaps the low deal activity in 2012 fed into the flurry of meetings at the next year’s BIO-Europe as companies looked to invest time to work toward their future partnerships. [Figure 2]
For a more detailed analysis of the above figures, and more, grab a copy of Partnering in the Pharma world: BIO-Europe® and Industry trends 2012–2015 when the next BIO-Europe takes place from November 7–9, 2016 in Cologne, Germany. Register for BIO-Europe online.